{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:14:34Z","timestamp":1785413674758,"version":"3.56.0"},"reference-count":34,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Grant-in-Aid for Early Career Scientists","doi-asserted-by":"publisher","award":["22K15049"],"award-info":[{"award-number":["22K15049"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Grant-in-Aid for Scientific Research","doi-asserted-by":"publisher","award":["24K08642"],"award-info":[{"award-number":["24K08642"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["22H05577"],"award-info":[{"award-number":["22H05577"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"award":["22H05577"],"award-info":[{"award-number":["22H05577"]}],"id":[{"id":"https:\/\/ror.org\/00hhkn466","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Japan Institute for Health Security (JIHS) Intramural Research Fund","award":["22T001"],"award-info":[{"award-number":["22T001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Various high-fat diets have been used to create animal models of metabolic dysfunction-associated steatotic liver disease (MASLD) and to evaluate the effect of various therapeutic drugs. We determined the effects of PPAR\u03b1\/\u03b4\/\u03b3 subtype-selective agonists (pemafibrate, seladelpar, and pioglitazone, respectively) on the hepatic triglyceride (TG) profile using LC\u2013MS in a MASLD mouse model established by administering a high-fat\/high-cholesterol\/high-cholic acid (HFCC) diet combined with cyclodextrin-containing water, which is thought to induce fatty liver over a short period. The livers of mice fed the HFCC\/CDX diet for four weeks exhibited an approximately fivefold increase in the summed TG LC\u2013MS signal per unit liver weight and altered TG composition compared with normal livers of mice administered a standard diet\/water. Specifically, the proportion of TG54 (TG with 54 carbon atoms) species doubled, whereas the proportion of TG52 decreased by 38%. Pemafibrate did not alter the relative total TG signal but decreased the proportion of some TG58\/TG56 species and increased the proportion of some TG56\/TG52 species. Seladelpar did not alter the relative total TG signal, while only slightly altering TG composition. Pioglitazone reduced the relative total TG signal by 44%, which included a decrease in the proportion of polyunsaturated fatty acid-rich TG54 and an increase in the proportion of TG58\/TG56 with 1\u20133 unsaturated bonds. We are the first to demonstrate that selective activation of PPAR\u03b1\/\u03b4\/\u03b3 has different effects on the TG profile in fatty liver.<\/jats:p>","DOI":"10.3390\/biom16081078","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:11:26Z","timestamp":1784797886000},"page":"1078","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Selective Pharmacological Activation of PPAR\u03b1\/\u03b4\/\u03b3 Alters the Triglyceride Composition of Fatty Liver in a Diet-Induced MASLD Mouse Model"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3167-6524","authenticated-orcid":false,"given":"Takako","family":"Hishiki","sequence":"first","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3611-5584","authenticated-orcid":false,"given":"Akihiro","family":"Honda","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Minomo","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otoe","family":"Minamisawa","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsubasa","family":"Konno","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Kamata","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waka","family":"Kamichatani","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzumi M.","family":"Tokuoka","sequence":"additional","affiliation":[{"name":"Department of Lipidomics, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7377-5956","authenticated-orcid":false,"given":"Yoshihiro","family":"Kita","sequence":"additional","affiliation":[{"name":"Department of Lipidomics, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Shindou","sequence":"additional","affiliation":[{"name":"Department of Lipid Life Science, Japan Institute for Health Security, Shinjuku, Tokyo 162-8655, Japan"},{"name":"Department of Medical Lipid Science, Graduate School of Medicine, The University of Tokyo, Bunkyo, Tokyo 113-0033, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5367-205X","authenticated-orcid":false,"given":"Isao","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Devasia, A.G., Ramasamy, A., and Leo, C.H. (2025). Current Therapeutic Landscape for Metabolic Dysfunction-Associated Steatohepatitis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26041778"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Prikhodko, V.A., and Okovityi, S.V. (2026). Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities. Biomedicines, 14.","DOI":"10.3390\/biomedicines14040909"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis","volume":"392","author":"Sanyal","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1172\/JCI88894","article-title":"Distinct but complementary contributions of PPAR isotypes to energy homeostasis","volume":"127","author":"Dubois","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Palomer, X., Wang, J.R., Tang, X., Wu, S., Rodr\u00edguez-Calvo, R., Wahli, W., and V\u00e1zquez-Carrera, M. (2026). Peroxisome Proliferator-Activated Receptor \u03b2\/\u03b4: A Link Between Metabolism, Inflammation, and Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease. Cells, 15.","DOI":"10.3390\/cells15050464"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Cheng, H.S., Tan, W.R., Low, Z.S., Marvalim, C., Lee, J.Y.H., and Tan, N.S. (2019). Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20205055"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"119432","DOI":"10.1016\/j.biopha.2026.119432","article-title":"Combination therapy with clinically approved PPAR\u03b1\/\u03b4\/\u03b3 subtype-selective agonists pemafibrate, seladelpar, and pioglitazone in a 4-week diet-induced early-stage MASLD mouse model","volume":"199","author":"Honda","year":"2026","journal-title":"Biomed. Pharmacother."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Kamata, S., Honda, A., and Ishii, I. (2023). Current clinical trial status and future prospects of PPAR-targeted drugs for treating nonalcoholic fatty liver disease. Biomolecules, 13.","DOI":"10.3390\/biom13081264"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/hep.31897","article-title":"A Systematic Review of Animal Models of NAFLD Finds High-Fat, High-Fructose Diets Most Closely Resemble Human NAFLD","volume":"74","author":"Im","year":"2021","journal-title":"Hepatology"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Alshawsh, M.A., Alsalahi, A., Alshehade, S.A., Saghir, S.A.M., Ahmeda, A.F., Al Zarzour, R.H., and Mahmoud, A.M. (2022). A Comparison of the Gene Expression Profiles of Non-Alcoholic Fatty Liver Disease between Animal Models of a High-Fat Diet and Methionine-Choline-Deficient Diet. Molecules, 27.","DOI":"10.3390\/molecules27030858"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"G508","DOI":"10.1152\/ajpgi.00139.2019","article-title":"Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis","volume":"317","author":"Duparc","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Recena Aydos, L., Aparecida do Amaral, L., Serafim de Souza, R., Jacobowski, A.C., Freitas Dos Santos, E., and Rodrigues Macedo, M.L. (2019). Nonalcoholic Fatty Liver Disease Induced by High-Fat Diet in C57bl\/6 Models. Nutrients, 11.","DOI":"10.3390\/nu11123067"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S0939-6411(98)00033-2","article-title":"Characterization of an inclusion complex of cholesterol and hydroxypropyl-beta-cyclodextrin","volume":"46","author":"Williams","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"104459","DOI":"10.1016\/j.xpro.2026.104459","article-title":"Protocol to purify fatty acid metabolites with two approaches for quantification using liquid chromatography-mass spectrometry","volume":"7","author":"Yamada","year":"2026","journal-title":"STAR Protoc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"19901","DOI":"10.1038\/s41598-024-71097-9","article-title":"Plasma proteomics and lipidomics facilitate elucidation of the link between Alzheimer\u2019s disease development and vessel wall fragility","volume":"14","author":"Tokuoka","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kita, Y., Tokuoka, S.M., Oda, Y., and Shimizu, T. (2022). TRACES: A Lightweight Browser for Liquid Chromatography-Multiple Reaction Monitoring-Mass Spectrometry Chromatograms. Metabolites, 12.","DOI":"10.3390\/metabo12040354"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"42774","DOI":"10.1074\/jbc.M306022200","article-title":"Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression","volume":"278","author":"Vergnes","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.jhep.2024.12.045","article-title":"Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD","volume":"82","author":"Barb","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e70558","DOI":"10.1111\/liv.70558","article-title":"Saroglitazar 4\u2009Mg in Metabolic Dysfunction-Associated Steatotic Liver Disease: 24-Week Results From Phase 4 Study","volume":"46","author":"Sanyal","year":"2026","journal-title":"Liver Int."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12933-024-02305-z","article-title":"Lessons from PROMINENT and prospects for pemafibrate","volume":"23","author":"Fruchart","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.clnu.2025.03.002","article-title":"Consumption of tree nuts as snacks stimulates changes in plasma fatty acid profiles and adipose tissue gene expression in young adults at risk for metabolic syndrome","volume":"48","author":"Widmer","year":"2025","journal-title":"Clin. Nutr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12933-017-0602-y","article-title":"Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia","volume":"16","author":"Fruchart","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","article-title":"Pemafibrate, a New Selective PPAR\u03b1 Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases","volume":"22","author":"Yamashita","year":"2020","journal-title":"Curr. Atheroscler. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"101727","DOI":"10.1016\/j.isci.2020.101727","article-title":"PPAR\u03b1 Ligand-Binding Domain Structures with Endogenous Fatty Acids and Fibrates","volume":"23","author":"Kamata","year":"2020","journal-title":"iScience"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Zhang, Z., Zhang, X., Qian, C., Diao, P., Nakajima, T., Kimura, T., Gonzalez, F.J., and Tanaka, N. (2026). Hepatocyte PPAR\u03b1 Is Essential for Triglyceride-Lowering Effect of Pemafibrate. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27073308"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.freeradbiomed.2021.06.017","article-title":"Beneficial effects of dietary supplementation with olive oil, oleic acid, or hydroxytyrosol in metabolic syndrome: Systematic review and meta-analysis","volume":"172","author":"Pastor","year":"2021","journal-title":"Free Radic. Biol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12986-026-01110-7","article-title":"The effect of oleic acid enriched diets on glucose and lipid metabolism: A systematic review and meta-analysis","volume":"23","author":"Xu","year":"2026","journal-title":"Nutr. Metab."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Zhu, B., Zhu, X., Borland, M.G., Ralph, D.H., Chiaro, C.R., Krausz, K.W., Ntambi, J.M., Glick, A.B., Patterson, A.D., and Perdew, G.H. (2024). Activation of Peroxisome Proliferator-Activated Receptor-\u03b2\/\u03b4 (PPAR\u03b2\/\u03b4) in Keratinocytes by Endogenous Fatty Acids. Biomolecules, 14.","DOI":"10.3390\/biom14060606"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1074\/jbc.M112.415729","article-title":"Oleic acid stimulates complete oxidation of fatty acids through protein kinase A-dependent activation of SIRT1-PGC1\u03b1 complex","volume":"288","author":"Lim","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Santa-Mar\u00eda, C., L\u00f3pez-Enr\u00edquez, S., Montserrat-de la Paz, S., Geniz, I., Reyes-Quiroz, M.E., Moreno, M., Palomares, F., Sobrino, F., and Alba, G. (2023). Update on Anti-Inflammatory Molecular Mechanisms Induced by Oleic Acid. Nutrients, 15.","DOI":"10.3390\/nu15010224"}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/8\/1078\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:46:35Z","timestamp":1784799995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/16\/8\/1078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["biom16081078"],"URL":"https:\/\/doi.org\/10.3390\/biom16081078","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]}}}